Ligand directed signaling differences between rodent and human κ-opioid receptors

Journal of Biological Chemistry

Volumn 287, Issue 50, 2012, Pages 41595-41607

  Schattauer, Selena S ^a   Miyatake, Mayumi ^a   Shankar, Haripriya ^a   Zietz, Chad ^a   Levin, Jamie R ^a   Liu Chen, Lee Yuan ^c   Gurevich, Vsevolod V ^d   Rieder, Mark J ^b   Chavkin, Charles ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c TEMPLE UNIVERSITY   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARRESTINS; G PROTEIN; HEK293 CELLS; LOW POTENCY; OPIOID RECEPTORS; P38 MAPK; PHOSPHORYLATION SITES;

AMINO ACIDS; LIGANDS; PHOSPHORYLATION; PROTEINS; SIGNALING;

CHEMICAL ACTIVATION;

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; BUTORPHANOL; GUANINE NUCLEOTIDE BINDING PROTEIN; KAPPA OPIATE RECEPTOR; LEVORPHANOL; MITOGEN ACTIVATED PROTEIN KINASE P38; NALORPHINE; NALOXONE; NALTREXONE; NORBINALTORPHIMINE; PENTAZOCINE; SERINE;

ANIMAL EXPERIMENT; ARTICLE; AVERSION; BINDING AFFINITY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; DRUG PROTEIN BINDING; ENZYME ACTIVATION; GENE MUTATION; HOMOLOGOUS RECOMBINATION; HOMOZYGOSITY; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; LIGAND BINDING; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PLACE PREFERENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

AMINO ACID SUBSTITUTION; ANALGESICS, OPIOID; ANIMALS; ENZYME ACTIVATION; HEK293 CELLS; HUMANS; LIGANDS; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, KNOCKOUT; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MUTATION, MISSENSE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; RECEPTORS, OPIOID, KAPPA; SPECIES SPECIFICITY;

MUS; RODENTIA;

EID: 84871268590     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.381368     Document Type: Article

References (44)

1. Fraser, H. F., and Rosenberg, D. E. (1964) Studies on the human addiction liability of 2′-hydroxy-5-9-dimethyl-2-(3,3-dimethylally)-6,7- benzomorphan (WIN 20,228). A weak narcotic antagonist. J. Pharmacol. Exp. Ther. 143, 149-156
2. Martin, W. R., Fraser, H. F., Gorodetzky, C. W., and Rosenberg, D. E. (1965) Studies of the dependence-producing potential of the narcotic antagonist 2-cyclopropylmethyl-2′-hydroxy-5,9-dimethyl-6,7-benzomorphan (cyclazocine, WIN-20,740, ARC II-c-3). J. Pharmacol. Exp. Ther. 150, 426-436
3. Martin, W. R. (1983) Pharmacology of opioids. Pharmacol. Rev. 35, 283-323
4. Pfeiffer, A., Brantl, V., Herz, A., and Emrich, H. M. (1986) Psychotomimesis mediated by κ opiate receptors. Science 233, 774-776
5. Mucha, R. F., and Herz, A. (1985) Motivational properties of κ and μ-opioid receptor agonists studied with place and taste preference conditioning. Psychopharmacology 86, 274-280 (Pubitemid 15064950)
6. Carlezon, W. A., Jr., Thome, J., Olson, V. G., Lane-Ladd, S. B., Brodkin, E. S., Hiroi, N., Duman, R. S., Neve, R. L., and Nestler, E. J. (1998) Regulation of cocaine reward by CREB. Science 282, 2272-2275 (Pubitemid 29004079)
7. Mague, S. D., Pliakas, A. M., Todtenkopf, M. S., Tomasiewicz, H. C., Zhang, Y., Stevens, W. C., Jr., Jones, R. M., Portoghese, P. S., and Carlezon, W. A., Jr. (2003) Antidepressant-like effects of κ-opioid receptor antagonists in the forced swim test in rats. J. Pharmacol. Exp. Ther. 305, 323-330 (Pubitemid 36373867)
8. McLaughlin, J. P., Marton-Popovici, M., and Chavkin, C. (2003) κ opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses. J Neurosci. 23, 5674-5683 (Pubitemid 36807845)
9. Land, B. B., Bruchas, M. R., Lemos, J. C., Xu, M., Melief, E. J., and Chavkin, C. (2008) The dysphoric component of stress is encoded by activation of the dynorphin κ-opioid system. J Neurosci. 28, 407-414
10. Rosow, C. E. (1987) The clinical usefulness of agonist-antagonist analgesics in acute pain. Drug Alcohol Depend. 20, 329-337
11. Wadenberg ML. (2003)Areview of the properties of spiradoline.Apotent and selective κ-opioid receptor agonist. CNS Drug Rev. 9, 187-198
12. Bruchas, M. R., Macey, T. A., Lowe, J. D., and Chavkin, C. (2006) κ opioid receptor activation of p38 MAPK is GRK3- and arrestin-dependent in neurons and astrocytes. J. Biol. Chem. 281, 18081-18089 (Pubitemid 44035608)
13. Land, B. B., Bruchas, M. R., Schattauer, S., Giardino, W. J., Aita, M., Messinger, D., Hnasko, T. S., Palmiter, R. D., and Chavkin, C. (2009) Activation of the κ opioid receptor in the dorsal raphe nucleus mediates the aversive effects of stress and reinstates drug seeking. Proc. Natl. Acad. Sci. U.S.A. 106, 19168-19173
14. Bruchas, M. R., Schindler, A. G., Shankar, H., Messinger, D. I., Miyatake, M., Land, B. B., Lemos, J. C., Hagan, C. E., Neumaier, J. F., Quintana, A., Palmiter, R. D., and Chavkin, C. (2011) Selective p38α MAPK deletion in serotonergic neurons produces stress resilience in models of depression and addiction. Neuron. 71, 498-511
15. McLaughlin, J. P., Xu, M., Mackie, K., and Chavkin, C. (2003) Phosphorylation of a carboxyl-terminal serine within the κ-opioid receptor produces desensitization and internalization. J. Biol. Chem. 278, 34631-34640 (Pubitemid 37553312)
16. Bruchas, M. R., Land, B. B., Aita, M., Xu, M., Barot, S. K., Li, S., and Chavkin, C. (2007) Stress-induced p38 mitogen-activated protein kinase activation mediates κ-opioid-dependent dysphoria. J. Neurosci. 27, 11614-11623 (Pubitemid 350006906)
17. Chavkin C. (2011) The therapeutic potential of κ-opioids for treatment of pain and addiction. Neuropsychopharmacology. 36, 369-370
18. Urban, J. D., Clarke, W. P., von Zastrow, M., Nichols, D. E., Kobilka, B., Weinstein, H., Javitch, J. A., Roth, B. L., Christopoulos, A., Sexton, P. M., Miller, K. J., Spedding, M., and Mailman, R. B. (2007) Functional selectivity and classical concepts of quantitative pharmacology. J. Pharmacol. Exp. Ther. 320, 1-13 (Pubitemid 46025713)
19. von Zastrow, M., Svingos, A., Haberstock-Debic, H., and Evans, C. (2003) Regulated endocytosis of opioid receptors. Cellular mechanisms and proposed roles in physiological adaptation to opiate drugs. Curr. Opin. Neurobiol. 13, 348-353 (Pubitemid 36792248)
20. Li, J., Li, J. G., Chen, C., Zhang, F., and Liu-Chen, L. Y. (2002) Molecular basis of differences in (-)(trans)-3,4-dichloro-N-methyl-N-[2-(1- pyrro-lidiny)-cyclohexyl]benzeneacetamide-induced desensitization and phosphorylation between human and rat κ-opioid receptors expressed in Chinese hamster ovary cells. Mol. Pharmacol. 61, 73-84 (Pubitemid 34049514)
21. Levine, J. D., Gordon, N. C., Taiwo, Y. O., and Coderre, T. J. (1988) Potentiation of pentazocine analgesia by low-dose naloxone. J. Clin. Invest. 82, 1574-1577 (Pubitemid 19007761)
22. 35S]GTPγS binding to membranes. Determination of potencies and efficacies of ligands. J. Pharmacol. Exp. Ther. 282, 676-684
23. Emmerson, P. J., Clark, M. J., Mansour, A., Akil, H., Woods, J. H., and Medzihradsky, F. (1996) Characterization of opioid agonist efficacy in a C6 glioma cell line expressing the μ-opioid receptor. J. Pharmacol. Exp. Ther. 278, 1121-1127 (Pubitemid 27166961)
24. Beaver, W. T., Wallenstein, S. L., Houde, R. W., and Rogers, A. (1966) A comparison of the analgesic effects of pentazocine and morphine in patients with cancer. Clin. Pharmacol. Ther. 7, 740-751
25. Hamilton, R. C., Dundee, J. W., Clarke, R. S., Loan, W. B., and Morrison, J. D. (1967) Studies of drugs given before anaesthesia. 13. Pentazocine and other opiate antagonists. Br. J. Anaesth. 39, 647-656
26. Jasinski, D. R., Martin, W. R., and Hoeldtke, R. D. (1970) Effects of short-and long-term administration of pentazocine in man. Clin. Pharmacol. Ther. 11, 385-403
27. Zacny, J. P., Hill, J. L., Black, M. L., and Sadeghi, P. (1998) Comparing the subjective, psychomotor, and physiological effects of intravenous pentazocine and morphine in normal volunteers. J. Pharmacol. Exp. Ther. 286, 1197-1207 (Pubitemid 29135530)
28. Preston, K. L., and Bigelow, G. E. (1993) Differential naltrexone antagonism of hydromorphone and pentazocine effects in human volunteers. J. Pharmacol. Exp. Ther. 264, 813-823 (Pubitemid 24283545)
29. Clarke, S., Czyzyk, T., Ansonoff, M., Nitsche, J. F., Hsu, M. S., Nilsson, L., Larsson, K., Borsodi, A., Toth, G., Hill, R., Kitchen, I., and Pintar, J. E. (2002) Autoradiography of opioid and ORL1 ligands in opioid receptor triple knockout mice. Eur. J. Neurosci. 16, 1705-1712 (Pubitemid 35370703)
30. Schuller, A. G., King, M. A., Zhang, J., Bolan, E., Pan, Y. X., Morgan, D. J., Chang, A., Czick, M. E., Unterwald, E. M., Pasternak, G. W., and Pintar, J. E. (1999) Retention of heroin and morphine-6 β-glucuronide analgesia in a new line of mice lacking exon 1 of MOR-1. Nat Neurosci. 2, 151-156 (Pubitemid 30491315)
31. Kovoor, A., Celver, J., Abdryashitov, R. I., Chavkin, C., and Gurevich, V. V. (1999) Targeted construction of phosphorylation-independent β-arrestin mutants with constitutive activity in cells. J. Biol. Chem. 274, 6831-6834
32. Celver, J., Vishnivetskiy, S. A., Chavkin, C., and Gurevich, V. V. (2002) Conservation of the phosphate-sensitive elements in the arrestin family of proteins. J. Biol. Chem. 277, 9043-9048 (Pubitemid 34952978)
33. Walther, C., Nagel, S., Gimenez, L. E., Mörl, K., Gurevich, V. V., and Beck-Sickinger, A. G. (2010) Ligand induced internalization and recycling of the human neuropeptide Y2 receptor is regulated by its C-terminal tail. J. Biol. Chem. 285, 41578-41590
34. Livingston, R. J., von Niederhausern, A., Jegga, A. G., Crawford, D. C., Carlson, C. S., Rieder, M. J., Gowrisankar, S., Aronow, B. J., Weiss, R. B., and Nickerson, D. A. (2004) Pattern of sequence variation across 213 environmental response genes. Genome Res. 14, 1821-1831 (Pubitemid 39386496)
35. Stephens, M., Sloan, J. S., Robertson, P. D., Scheet, P., and Nickerson, D. A. (2006) Automating sequence-based detection and genotyping of SNPs from diploid samples. Nat. Genet. 38, 375-381
36. Remmers, A. E., Clark, M. J., Mansour, A., Akil, H., Woods, J. H., and Medzihradsky, F. (1999) Opioid efficacy in a C6 glioma cell line stably expressing the human κ opioid receptor. J. Pharmacol. Exp. Ther. 288, 827-833 (Pubitemid 29119701)
37. McLennan, G. P., Kiss, A., Miyatake, M., Belcheva, M. M., Chambers, K. T., Pozek, J. J., Mohabbat, Y., Moyer, R. A., Bohn, L. M., and Coscia, C. J. (2008) κ opioids promote the proliferation of astrocytes viaGβγ and β-arrestin 2-dependent MAPK-mediated pathways. J. Neurochem. 107, 1753-1765
38. Suzuki, T., Narita, M., Misawa, M., and Nagase, H. (1991) Pentazocine-induced biphasic analgesia in mice. Life Sci. 48, 1827-1835
39. Gurevich, V. V., and Gurevich, E. V. (2006) The structural basis of arrestin-mediated regulation of G-protein-coupled receptors. Pharmacol. Ther. 110, 465-502
40. Hiramatsu, M., and Hoshino, T. (2005) Improvement of memory impairment by (+)- and (-)-pentazocine via δ but not κ opioid receptors. Brain Res. 1057, 72-80 (Pubitemid 41338089)
41. Mori, T., Yoshizawa, K., Nomura, M., Isotani, K., Torigoe, K., Tsukiyama, Y., Narita, M., and Suzuki, T. (2012) δ1 receptor function is critical for both the discriminative stimulus and aversive effects of the κ-opioid receptor agonist U-50488H. Addict Biol. 17, 717-724
42. Ide, S., Minami, M., Uhl, G. R., Satoh, M., Sora, I., and Ikeda, K. (2011) (-)-Pentazocine induces visceral chemical antinociception, but not thermal, mechanical, or somatic chemical antinociception, in μ-opioid receptor knockout mice. Mol. Pain 7, 23
43. Chien, C. C., and Pasternak, G. W. (1995) (-)-Pentazocine analgesia in mice. Interactions with a δ receptor system. Eur. J. Pharmacol. 294, 303-308
44. Shu, H., Hayashida, M., Arita, H., Huang, W., Zhang, H., An, K., Wu, G., and Hanaoka, K. (2011) Pentazocine-induced antinociception is mediated mainly by μ-opioid receptors and compromised by κ-opioid receptors in mice. J. Pharmacol. Exp. Ther. 338, 579-587